Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

Peripheral artery disease affects approximately 236 million persons worldwide and is diagnosed with an ankle–brachial index of less than 0.90. Among older persons, 3.3% of those without peripheral ...

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia HELSINKI, 12 March 2026 - Aplagon, a ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

"Our findings highlight the clinical importance of focusing on total disease burden, rather than first events, and the need for long-term preventive strategies in high-risk patients."—Michael Szarek, ...

Compared with white patients, Black patients with PAD who undergo peripheral revascularization have much more advanced disease at the time of their procedures and are less likely to receive necessary ...

New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and ...

Among older veterans with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors as an add-on therapy is associated with a higher risk for peripheral artery disease ...